Big ideas with the power for change are the cornerstone on which Edwards Lifesciences was founded. So when we ask ourselves, is it possible? The answer must be yes. Because improving the quality of life for structural heart patients around the world has always been our mission.

Learn how Edwards Lifesciences is enabling better quality of care for patients through structural heart disease awareness and aortic heart valve replacement approaches.

American heart association

initiative aims to improve the outcomes of patients living with aortic stenosis. Learn more

Transcatheter heart valves

Transcatheter heart valves

Discover more
Surgical valve technologies

Surgical valve technologies

Discover more

Not just for older patients anymore

The latest guidelines recommend tissue valves for patients as young as 50 years old.

2014 AHA/ACC guidelines were updated in 2017 to expand the age consideration of either a tissue or a mechanical valve from 60-70 years of age to now include younger patients between 50-70 years of age.

2017 AHA/ACC guidelines of valve type by patient age

2017 AHA/ACC guidelines

Tissue and mechanical valve comparison summary

Tissue valves Tissue valvesMechanical valves Mechanical valves
Long-term blood thinner required No Yes Daily blood thinner medication and regular blood tests for rest of life
Valve longevity 10 to over 20 years, depending on type of valve, patient characteristics, and other factors RESILIA tissue has been shown in animal studies to have less calcium build-up, potentially allowing the valve to last longer.1* Over 20 years, in general
Lifestyle and dietary considerations Yes May need to reduce calcium intake Yes Limits active lifestyle and foods high in vitamin K (such as leafy greens) from diet
Noticeable sounds from valve No Yes Clicking sound as valve opens and closes
Pregnancy considerations No No known pregnancy complication risk Yes High pregnancy complication risks due to use of blood thinners

1*RESILIA tissue has not been studied for long term results in patients.

The right choice today.

Because today, your patients want an improved quality of life and the potential to expand their future options.

Built with RESILIA tissue, the INSPIRIS RESILIA aortic valve is designed to offer enhanced tissue anti-calcification technology that will potentially allow the valve to last longer.1

The INSPIRIS RESILIA valve delivers on the promise of better ongoing patient quality of life without the inconvenience of monitoring, dietary restrictions and reduction of participation in active lifestyles typically seen with a mechanical valve.2,3

Valve today

The INSPIRIS valve possesses many advantages over a mechanical valve:

  • Freedom to live a more active lifestyle
  • Fewer dietary restrictions
  • No need for long-term anticoagulants
  • No clicking sound with every heartbeat

No clinical data are available that evaluate the long-term impact of RESILIA tissue in patients.

Ready for tomorrow.

Help your patients meet the future confidently, with enhanced options for subsequent valve intervention.

The INSPIRIS aortic valve incorporates novel VFit technology, designed to enable valve-in-valve procedures in the future, at a time when patients are older and potentially at a higher risk for complications.

valve tomorrow

Proven performance for your patients

Backed by a strong and growing base of preclinical and clinical evidence supporting its ongoing study of durability and hemodynamic performance.1, 4, 5

european-feasibility-trial

european-feasibility-trial

Expanding future possibilities for you and your patients starts today.

“Patients undergoing a valve replacement are living long lives and remaining more active through their later years, increasing the need for advanced valve replacement technologies. The absence of structural valve deterioration in these patients is extremely encouraging and highlights the potential of valves containing RESILIA tissue for patients who may otherwise opt for a mechanical valve, which requires long-term use of blood thinning medications.”
John D. Puskas, MD Principal investigator for the COMMENCE study
COMMENCE Trial Clinical Summary

COMMENCE Trial Clinical Summary

The COMMENCE trial: Four-year outcomes with an aortic bioprosthesis with RESILIA tissue.

Download brochure

Sign-up for updates

Receive expert educational materials, including:

TAVR data
Information on the latest data
Special resources
Access to special resources
Receive updates
Important updates for you, your staff, and your patients
Get alerted
Alerts when new patient and HCP resources become available

Professional information

Thank you

Your form was successfully submitted. An Edwards representative will contact you shortly.

Contact information

Professional information

Location

Inquiry

Would you like to opt-in to receive future email communications from Edwards Lifesciences?
This includes notification of future symposia, forums, conference activities, product updates, and educational events.*

Opt in

For additional information, please read our privacy policy.

Transcatheter heart valves

Transcatheter heart valves

Discover more

References

  1. FlamengW, et al. A randomized assessment of an advanced tissue preservation technology in the juvenile sheep model. J ThoracCardiovasc Surg. 2015; 149:340–5.
  2. Ruel M, et al. Long-term outcomes of valve replacement with modern prostheses in young adults. Eur J Cardiothorac Surg. 2005;27(3):425–433.
  3. Kottmaier M, et al. Quality of Life and Anxiety in Younger Patients after Biological versus Mechanical Aortic Valve Replacement. Thorac Cardiovasc Surg. 2017;65(3):198–205.
  4. Johnston DR, et al. Intermediate-term outcomes of aortic valve replacement using a bioprosthesiswith a novel tissue. J ThoracCardiovasc Surg. 2020. 5. Bartus K, et al., Five-year Outcomes of Aortic Valve Replacement Using a Bioprosthetic Valve with the Novel RESILIA Tissue: Final Study Results. Structural Heart, 2019; vol3, no.S1, 18.
  5. Bartus K, et al., Five-year Outcomes of Aortic Valve Replacement Using a Bioprosthetic Valve with the Novel RESILIA Tissue: Final Study Results. Structural Heart, 2019; vol3, no.S1, 18

Please update your browserClose this window

Please update to a current version of your preferred browser, this site will perform effectively on the following:

Unable to update your browser?

If you are on a computer, that is maintained by an admin and you cannot install a new browser, ask your admin about it. If you can't change your browser because of compatibility issues, think about installing a second browser for browsing and keep this old one for compatibility